⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL247259 | 0.97 | ACLY (0.45) | — | |
| Iodomethane SCHEMBL7525088 | 0.95 | ACLY (0.43) | — | |
| SCHEMBL2227906 | 0.84 | ACLY (0.54) | — | |
| SCHEMBL9718212 | 0.82 | ACLY (0.57) | — | |
| SCHEMBL10548846 | 0.82 | ACLY (0.52) | — | |
| Hydrochloric Acid SCHEMBL3506267 | 0.82 | ACLY (0.52) | — | |
| SCHEMBL320771 | 0.82 | ACLY (0.54) | — | |
| SCHEMBL10870280 | 0.80 | ACLY (0.61) | — | |
| SCHEMBL20798639 | 0.80 | KDM4E (0.37) | — | |
| SCHEMBL28439734 | 0.80 | ACLY (0.61) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 387 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120117870-A | Concrete prepared based on regenerated fibers and preparation method thereof | 中建西部建设第九有限公司 | 2025-06-10 | — | — | CN | claimed |
| CN-108349960-B | Nostoc compounds and conjugates, their preparation and their therapeutic use | 赛诺菲 | 2022-05-27 | — | — | CN | claimed |
| US-20210163458-A1 | NOVEL CRYPTOPHYCIN COMPOUNDS AND CONJUGATES, THEIR PREPARATION AND THEIR THERAPEUTIC USE | SANOFI SA (FR) | 2021-06-03 | — | — | US | claimed |
| US-11007275-B2 | Cryptophycin antibody conjugates for the treatment of cancer | SANOFI (FR) | 2021-05-18 | — | — | US | claimed |
| US-20210023094-A1 | PSMA ANTIBODY-DRUG CONJUGATES | PSMA DEVELOPMENT COMPANY, LLC (US) | 2021-01-28 | — | — | US | claimed |
| EP-3371179-B1 | NOVEL CRYPTOPHYCIN COMPOUNDS AND CONJUGATES, THEIR PREPARATION AND THEIR THERAPEUTIC USE | SANOFI SA (FR) | 2019-08-07 | — | — | EP | claimed |
| EP-3371179-A1 | NOVEL CRYPTOPHYCIN COMPOUNDS AND CONJUGATES, THEIR PREPARATION AND THEIR THERAPEUTIC USE | SANOFI (FR) | 2018-09-12 | — | — | EP | claimed |
| CN-108349960-A | New nostoc element compound and conjugate, their preparation and their therapeutical uses | 赛诺菲 | 2018-07-31 | — | — | CN | claimed |
| WO-2017076998-A1 | NOVEL CRYPTOPHYCIN COMPOUNDS AND CONJUGATES, THEIR PREPARATION AND THEIR THERAPEUTIC USE | SANOFI (FR) | 2017-05-11 | — | — | WO | claimed |
| CN-102639545-B | The method preparing hydroxy amino di 2 ethylhexyl phosphonic acid | 施里特马克控股公司 | 2016-08-03 | — | — | CN | claimed |
| EP-1718667-A4 | HETEROCYCLIC SELF-IMMOLATIVE LINKERS AND CONJUGATES | GENENTECH INC (US) | 2009-04-08 | — | — | EP | claimed |
| US-20090041791-A1 | Heterocyclic self-immolative Linkers and Conjugates | SEAGEN INC. | 2009-02-12 | — | — | US | claimed |
| EP-1912677-A2 | PSMA ANTIBODY-DRUG CONJUGATES | Psma Development Company, L.L.C. (US) | 2008-04-23 | — | — | EP | claimed |
| WO-2007002222-A2 | PSMA ANTIBODY-DRUG CONJUGATES | PSMA DEVELOPMENT COMPANY, LLC (US) | 2007-01-04 | — | — | WO | claimed |
| EP-1718667-A2 | HETEROCYCLIC SELF-IMMOLATIVE LINKERS AND CONJUGATES | GENENTECH, INC. (US) | 2006-11-08 | — | — | EP | claimed |
| US-20050256030-A1 | for linking drug moieties to ligands; comprises a peptide sequence that is a substrate for an intracellular enzyme, for example a cathepsin, that cleaves the peptide at an amide bond | SEAGEN INC. | 2005-11-17 | — | — | US | claimed |
| WO-2005082023-A2 | HETEROCYCLIC SELF-IMMOLATIVE LINKERS AND CONJUGATES | GENENTECH, INC. (US) | 2005-09-09 | — | — | WO | claimed |
| EP-0624377-B1 | Lysosomal enzyme-cleavable antitumor drug conjugates | BRISTOL MYERS SQUIBB CO (US) | 2002-01-23 | — | — | EP | claimed |
| US-6214345-B1 | ANTITUMOR AGENTS; DRUG CONJUGATES WHICH ARE SELECTIVELY ACTIVATIBLE AT THE SITE OF THE TUMOR | BRISTOL-MYERS SQUIBB CO. | 2001-04-10 | — | — | US | claimed |
| EP-0624377-A2 | Lysosomal enzyme-cleavable antitumor drug conjugates | Bristol-Myers Squibb Company (US) | 1994-11-17 | — | — | EP | claimed |